Most importantly, the methylation status of ZNF132 promoter in the tumor tissues of ESCC patients is an independent prognostic factor, and has the potential use as a biomarker useful in prognosis of ESCC. This evidence concerns the gene ZNF132 and esophageal squamous cell carcinoma.